The Evaluation of Thyroid Functions, Thyroid Antibodies, and Thyroid Volumes in Children with Epilepsy during Short‐Term Administration of Oxcarbazepine and Valproate

• Published in: Epilepsia (Copenhagen) 2006-11, Vol.47 (11), p.1855-1859
• Main Authors: Cansu, Ali, Serdaroğlu, Ayşe, Çamurdan, Orhun, Hırfanoğlu, Tuğba, Bideci, Aysun, Gücüyener, Kıvılcım
• Format: Article
• Language: English
• Subjects: Antibodies - analysis; Antibodies - immunology; Anticonvulsants - pharmacology; Anticonvulsants - therapeutic use; Anticonvulsants. Antiepileptics. Antiparkinson agents; Biological and medical sciences; Carbamazepine - analogs & derivatives; Carbamazepine - pharmacology; Carbamazepine - therapeutic use; Child; Children; Drug Administration Schedule; Drug toxicity and drugs side effects treatment; Epilepsy; Epilepsy - blood; Epilepsy - drug therapy; Epilepsy - immunology; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy; Humans; Iodide Peroxidase - immunology; Iodine - urine; Longitudinal Studies; Medical sciences; Nervous system (semeiology, syndromes); Neurology; Neuropharmacology; Oxcarbazepine; Pharmacology. Drug treatments; Thyroid Function Tests; Thyroid functions; Thyroid Gland - anatomy & histology; Thyroid Gland - immunology; Thyroid Hormones - blood; Time Factors; Toxicity: digestive system; Valproate; Valproic Acid - pharmacology; Valproic Acid - therapeutic use
• ISSN: 0013-9580; 1528-1167
• DOI: 10.1111/j.1528-1167.2006.00821.x

Purpose: The aim of this study was to evaluate the effects of short‐term oxcarbazepine (OXC) and valproate (VPA) monotherapy on thyroid functions in children. Methods: Fifty‐five newly diagnosed epileptic children with normal thyroid functions (confirmed with the thyrotropin releasing hormone stimulation test) participated in this study. VPA treatment was started in 30 patients and OXC in 25 patients. Serum thyroxine (T4), free thyroxine (fT4), triiodothyronine (T3), free triiodothyronine (fT3), reverse T3 (rT3), thyroid peroxidase antibodies (TPO‐ab), and urine iodine levels were evaluated at baseline and at the third and sixth months of therapy. Results: In the OXC group, serum T4, fT4, T3, fT3, and rT3 levels were found to be decreased at the third and sixth months, the differences were significant compared to the baseline values except for fT3 levels at the third month and fT4 and rT3 levels at the sixth month (p < 0.05). At the sixth month, serum T4 level dropped below the normal reference value in 8 (32%), fT4 in 5 (20%), T3 in 4 (16%), and fT3 in 3 (12%) patients. In the VPA group, mean T4, fT4, T3, fT3, and rT3 levels at 3 and 6 months remained similar compared to the baseline values (p > 0.05). Mean serum thyroid stimulating hormone levels increased significantly at the sixth month compared to the baseline values in the VPA group (p < 0.05) while it remained unchanged in the OXC group (p > 0.05). There was no effect of either drug on urinary iodine excretion and serum TPO‐ab levels remained in normal ranges throughout the study. Conclusions: In this prospective study, it is documented that children under short‐term OXC or VPA therapy showed altered thyroid functions similar to the changes observed after long‐term treatment. Although, the clinical significance of these results need to be evaluated with future studies, this observation of altered thyroid functions points out that thyroid functions may need to be monitored closely in children receiving antiepileptic treatment, even in the short‐time interval.